WO2003012080A2 - Selection ex vivo de lymphocytes t - Google Patents
Selection ex vivo de lymphocytes t Download PDFInfo
- Publication number
- WO2003012080A2 WO2003012080A2 PCT/EP2002/008052 EP0208052W WO03012080A2 WO 2003012080 A2 WO2003012080 A2 WO 2003012080A2 EP 0208052 W EP0208052 W EP 0208052W WO 03012080 A2 WO03012080 A2 WO 03012080A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- allogeneic
- binding molecules
- cell
- combinations
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 102
- 238000010322 bone marrow transplantation Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 46
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 33
- 230000008105 immune reaction Effects 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 145
- 210000000130 stem cell Anatomy 0.000 claims description 57
- 230000000735 allogeneic effect Effects 0.000 claims description 44
- 208000032839 leukemia Diseases 0.000 claims description 39
- 210000004443 dendritic cell Anatomy 0.000 claims description 37
- 102100035793 CD83 antigen Human genes 0.000 claims description 36
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 35
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 34
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 34
- 210000004698 lymphocyte Anatomy 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 101150013553 CD40 gene Proteins 0.000 claims description 29
- 230000006907 apoptotic process Effects 0.000 claims description 27
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 24
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 22
- 101150064015 FAS gene Proteins 0.000 claims description 22
- 108090000174 Interleukin-10 Proteins 0.000 claims description 22
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 238000003782 apoptosis assay Methods 0.000 claims description 22
- 230000005522 programmed cell death Effects 0.000 claims description 22
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 21
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 21
- 102000003814 Interleukin-10 Human genes 0.000 claims description 20
- 108700012411 TNFSF10 Proteins 0.000 claims description 20
- 210000001185 bone marrow Anatomy 0.000 claims description 20
- 229940076144 interleukin-10 Drugs 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 210000003289 regulatory T cell Anatomy 0.000 claims description 16
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 15
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 15
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 14
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 14
- 210000000170 cell membrane Anatomy 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 12
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 11
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 11
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 102100026761 Eukaryotic translation initiation factor 5A-1 Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 8
- 210000001616 monocyte Anatomy 0.000 claims description 8
- 230000000961 alloantigen Effects 0.000 claims description 7
- 230000004940 costimulation Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 108010045634 B7 Antigens Proteins 0.000 claims description 6
- 102000005738 B7 Antigens Human genes 0.000 claims description 6
- -1 B7 binding molecules Proteins 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 239000011647 vitamin D3 Substances 0.000 claims description 6
- 229940021056 vitamin d3 Drugs 0.000 claims description 6
- KDYRQBCJBKCHIQ-UHFFFAOYSA-N Hypusin Natural products NCC(O)CNCCCCC(N)C(=O)O KDYRQBCJBKCHIQ-UHFFFAOYSA-N 0.000 claims description 5
- 108700005077 Viral Genes Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 3
- 229960005084 calcitriol Drugs 0.000 claims description 3
- 108010052621 fas Receptor Proteins 0.000 claims description 3
- 102000018823 fas Receptor Human genes 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 235000005282 vitamin D3 Nutrition 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000227 bioadhesive Substances 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000002288 golgi apparatus Anatomy 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 210000003412 trans-golgi network Anatomy 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- PNVHJVAEGZHXIL-UHFFFAOYSA-N 2,8-diaminooctanimidamide Chemical compound NCCCCCCC(N)C(N)=N PNVHJVAEGZHXIL-UHFFFAOYSA-N 0.000 claims 1
- 101150007193 IFNB1 gene Proteins 0.000 claims 1
- 101150106931 IFNG gene Proteins 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 21
- 208000024908 graft versus host disease Diseases 0.000 description 21
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 7
- 208000024207 chronic leukemia Diseases 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 208000004736 B-Cell Leukemia Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 108091008034 costimulatory receptors Proteins 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Substances [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011735 C3H mouse Methods 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000899 immune system response Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 238000006222 Berchtold homologation reaction Methods 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010052382 CD83 antigen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011129 allogeneic cell therapy Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 101150074736 eif5a gene Proteins 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- RKWPZPDLTYBKCL-RVZGXXANSA-N meproscillarin Chemical compound O[C@@H]1[C@H](O)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C=C2CC[C@H]3[C@@]4(O)CC[C@H](C5=COC(=O)C=C5)[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1 RKWPZPDLTYBKCL-RVZGXXANSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to antigen-presenting cells, methods for producing antigen-presenting cells, medicaments containing antigen-presenting cells and use of the antigen-presenting cells.
- Tissue transplantation to replace diseased organs is an important medical therapy today.
- an adaptive immune system response to the graft poses the greatest threat to successful treatment.
- Adaptive immune system responses are induced by antigen presenting cells by activating T helper lymphocytes.
- the ABO and Rh blood group antigens When transfusing blood, which is the first and most commonly used graft, the ABO and Rh blood group antigens must be matched to avoid the rapid destruction of inappropriate erythrocytes.
- the very polymorphic major histocompatibility complexes Tissue Compatibility Complexes, MHC
- MHC tissue Compatibility Complexes
- Leukemia is cancer of the blood cells. 50 out of 1 million people get leukemia every year. When leukemia develops, the body produces large amounts of abnormal blood cells. In most types of leukemia, the abnormal cells are white blood cells.
- leukemia There are several types of leukemia, which essentially show two characteristics. One characteristic is how quickly the disease develops and worsens. The other is determined by the type of blood cell that is affected.
- Leukemia is either acute or chronic. In acute leukemia, the abnormal blood cells are very immature blasts that cannot perform their normal functions. The number of blasts increases rapidly and the ailments quickly get worse. Some blasts are present in chronic leukemia, but generally these cells are more mature and can perform some of their normal functions. The number of blasts also rises more slowly than with acute leukemia. With chronic leukemia, the disease gradually gets worse.
- Leukemia essentially appears in two main types of white blood cells, lymphoid cells or myeloid cells. Accordingly, leukemia occurs as lymphatic leukemia or . myeloid leukemia. The most common leukemias are:
- ALL Acute lymphoblastic leukemia
- AML Acute myeloid leukemia
- ANLL acute non-lymphoblastic leukemia
- CLL Chronic lymphoblastic leukemia
- CML Chronic myeloid leukemia
- Leukaemic cells are abnormal cells that cannot function as normal blood cells. They cannot help the body fight infections. Because of this, people with leukemia often develop infections and have a fever.
- leukemic cells Like all blood cells, leukemic cells circulate in the body. Due to the number of abnormal cells and their location, patients with leukemia can show various symptoms. In acute leukemia, symptoms appear quickly and the patient's condition also deteriorates rapidly. Chronic leukemia appears
- symptoms for a long time. When symptoms appear, they are usually mild at first and the patient's general condition only gradually worsens.
- the abnormal cells can collect in the brain or spinal cord (central nervous system or CNS).
- CNS central nervous system
- the result can be headache, nausea, nausea, confusion, loss of muscle control and strokes.
- Leukaemic cells can also collect in the testes and cause swelling there. Some patients develop painful eyes or skin. Leukemia can also affect the digestive tract, kidneys, lungs, or other parts of the body.
- Chronic leukemia With chronic leukemia, the abnormal cells can gradually collect in different parts of the body. Chronic leukemia can affect the skin, CNS, digestive tract, kidneys and testicles. Treatment of leukemia:
- Treating leukemia is complex. It varies with the type of leukemia and is not the same in all patients. Treatment also depends on
- the leukemic cells certain characteristics of the leukemic cells, the extent of the disease, whether the leukemia has been treated before. The patient's age, symptoms and general health are also relevant factors.
- Acute leukemia must be treated immediately. Patients with chronic leukemia who show no symptoms do not need to be treated immediately. Unfortunately, chronic leukemia can rarely be cured.
- KMT bone marrow transplantation
- BMT bone marrow transplantation
- removal of the spleen can help.
- patients receive full body radiation combined with chemotherapy to destroy the leukemia-producing bone marrow.
- the healthy bone marrow can come from a donor or it can come from the patient. It is then removed and treated outside the body to remove leukemic cells before high dose treatment. After that, a hospital stay of several weeks is necessary so that the transplant grows and enough white blood cells (leukocytes), such as T, B lymphocytes, neutrophils, basophils and eosinophils, platelets (platelets), monocytes and other subpopulations for the reconstitution (restoration) of the hematopoietic hematopoietic) system can produce. In the meantime, patients need to be protected from infection.
- the biological therapies include treatments with substances that influence the immune response to cancer. Cytokines, such as especially interferons, interleukins and colony stimulating factors (CSF) are used for example
- GVHD graft versus host disease
- BMT Allologic bone marrow transplantations
- CML chronic myeloid leukemia
- CML is characterized in the early chronic phase by a single transformative genetic abnormality identified. It is the t (9; 22) translocation (Philadelphia Chromosome, Ph) that the bcr-abl oncogene creates, the only factor that is essential for the development of the Disease is needed (Daley et al 1990). Compared to other tumor types in the chronic phase, CML patients have a relatively intact immune system (Lewalle et al 1996). CML is accessible for a tumor-specific immune response. In the past 20-30 years, anti-tumor
- Allo-BMT is a fairly rough approach with significant graft-related morbidity and mortality. The risk of dying is 20-41% (Silver et al 1999). This form of immunotherapy also offers egg ne up to 70% leukemia-free survival rate for the transplant recipients (Clift &. Anasetti 1997). This GvHD overlays the desired anti-leukemic effect.
- Bone marrow transplants are also used for other leukemias.
- GvHD graffc versus host disease
- mucous membranes and conjunctiva dry out and myositis.
- immunosuppression is carried out with cyclosporin, possibly in combination with methotrexate and corticosteroids.
- T lymphocytes in the graft reduces the risk of GvHD.
- the risk of tumor recurrence increases because the donor T lymphocytes also mediate the favorable graft versus leukemia effect (GvL). If you want to maintain the GvL effect while reducing the GvHD risk, you have to partially deplete the T cells and gradually reinfuse the donor T lymphocytes at later times. _ g.
- FasL is known as a potent apoptosis-inducing molecule (membrane protein). It communicates its effects via Fas, a receptor that occurs on T cells. If DCs are transfected with FasL, they induce apoptosis in
- FasL-transfected DCs can cause an Ag-specific reduction in graft rejection. This is based on the interaction (apoposis induction) of FasL on DCs and Fas receptor on the T cells (Min et al 2000).
- TRAIL tumor necrosis factor-related apoptosis-inducing ligand
- DCs arise from circulating progenitor cells after a maturation period.
- DCs can be characterized by a specific population of marker molecules. These include accessory, costimulatory gene products such as CD40, CD80, and CD86 as well as MHC class I and II.
- the CD83 molecule in particular is a well-characterized marker for fully mature DCs, since CD83 cannot be detected on immature DC precursors.
- the functional significance of CD83 is unknown. Its increasing presence during the ripening indicates an important function (Berchtold et al 1999).
- Herpes simplex virus is able to suppress the expression of CD83 in an unexplained manner, while the production of other molecules typical of DCs such as CD25, CD40, CD80, CD86, CD95 and MHC of class I and class II remains unaffected (Kruse et al 2000b).
- Inhibition of CD83 expression on the plasma membrane leads to a dramatic reduction in DC-mediated T cell stimulation. If the eukaryotic initiation factor 5A is hindered by a specific inhibitor, CD83 expression can be prevented, which also leads to a strong reduction in DC-mediated T cell stimulation (Kruse et al 2000a).
- eIF-5A is a
- Protein that is included in the export path of specific RNAs from the cell nucleus Protein that is included in the export path of specific RNAs from the cell nucleus.
- eIF-5A is the only cellular protein known to contain the unusual amino acid hypusin. This modification appears to be necessary for cell division.
- Hypusin modification is a spermidine-dependent post-translational reaction that is catalyzed by two enzymes. This includes the transfer of the aminobutyl group of spermidine to the ⁇ -NH 2 group of lysine at position 50 in eIF-5A by the deoxyhypusin synthase (Kruse et al 2000a).
- eIF-5A is then hydroxylated by the deoxyhypusin hydroxylase. In this way the active form of eIF-5A is created.
- eIF-5A was originally referred to as an "initiation factor"
- recent in vitro and in vivo experiments have shown that eIF-5A is not an initiator of protein translation.
- eIF-5A appears to be part of a specific export path from the cell nucleus, which is used, for example, by the Rev / Rex class of retroviral RNA transport factors. It was also shown that the eIF-5A protein accumulates on the nucleoplasmic side of the nuclear pore complex in order to interact with the general nuclear export receptor CRM1 and to migrate from the nucleus into the cytoplasm in mammalian cells.
- eIF-5A is constitutively expressed in cell lines as well as various other tissues.
- the eIF-5A gene is induced in primary lymphoid cells during the activation and / or proliferation of primary human blood cells. If an inhibitor of hypusin modification [GC7 (N 1 - guanyl-l, 7-diaminoheptan)], the expression of CD83 and thus the full stimulatory activity of mature DCs is inhibited (Kruse et al 2000a).
- the cell according to the invention is preferably a dendritic cell or another antigen-presenting cell or one of the precursors of such a cell.
- the APCs are the switching points of the adaptable immune system. Only they can trigger or stop a T cell-mediated immune response.
- the allologic immune reactions cannot be maintained without the help and mediation of APCs and T-helper lymphocytes.
- the cytotoxic T cells are also activated by APCs. They mediate a cellular immune response in which cells are killed directly by the cytotoxic T cells.
- the molecular mechanisms of interaction - cell-cell contact - of APCs with the T helper and cytotoxic T lymphocytes are known in detail at the receptor level.
- the antigen is e.g. a bacterial protein
- the immune response is useful for the organism.
- the antigen is a transplant antigen, one speaks of a (pathological) rejection reaction.
- WO 01/29192 discloses a method of using antigen-presenting cells to prevent GvHD effects. However, the antigen-presenting cells are co-incubated with dead or dying cell parts of the transplant recipient in order to contain loaded antigen-presenting cells
- the cell components should contain antigens for which a reduction in an immune response is desired. According to the invention, this step is not required since cells of the receiver are used. In addition, further changes are made or immature DCs are used to reduce a repulsive immune response.
- the problem on which the invention is based is, inter alia, to make available therapeutically usable products for the reduction of allologic immune reactions in bone marrow transplants.
- Figure 1 shows the recovery of non-alloreactive T cells with mature DC.
- Figure 2 shows the extraction of non-alloreactive T cells with immature DC.
- Figure 3 shows the treatment scheme for DC from Balb / c mice.
- Figure 4 shows the first and second incubation of T cells with alloglogic cells.
- Figure 5 shows CD86 expression of the Balb / c-DC before starting the first incubation.
- Figure 6 shows the cytotoxicity of the CD8 + T cells, which were incubated in the first incubation with differently treated DC.
- the problem is solved by cells of the recipient which are antigen-presenting cells or are cells from which antigen-presenting cells can be generated.
- the antigen-presenting cells are the dendritic cells, but also B cells.
- the antigen-presenting cells are to be incubated with allologic bone marrow beam planets. These grafts contain lymphocytes.
- the antigen-presenting cells can can also be incubated alone with the lymphocytes or T cells (T lymphocytes).
- T lymphocytes T lymphocytes
- T-lymphocytes T cells
- the T cells are of particular interest because they are important reactions for the recipient / patient
- the useful response is anti-leukemic GvL
- the harmful response is GvHD.
- the incubation of the antigen-presenting cells with the transplant and here in particular with the T cells occurring therein is said to switch off the GvHD reaction and to maintain only the GvL reaction.
- the antigen-presenting cells are selected or treated in such a way that they can no longer activate T cells, but can still present the recipient's alloantigens. If an alloreactive T cell encounters such an antigen-presenting cell, it is permanently shut down, or sent to programmed cell death (apoptosis), or converted into a regulatory T cell.
- a regulatory T cell is understood to be a T cell that prevents immune responses to specific antigens, here alloantigens. The following are ways to solve the problem:
- the cell according to the invention which originates from the recipient of the transplant and is characterized in that one of the functions of co-stimulatory receptors, such as a CD83 receptor and / or B7 and / or CD40 receptor, is suppressed and / or CTLA4-binding molecules are added which bind CTLA4 to T cells of the transplant and / or Fas binding molecules are added which bind the Fas to T cells of the transplant and / or TRAIL receptor binding molecules are added, bind the TRAIL receptors to T cells of the graft, or interleukin 10 (IL-10) is added.
- co-stimulatory receptors such as a CD83 receptor and / or B7 and / or CD40 receptor
- CTLA4-binding molecules are added which bind CTLA4 to T cells of the transplant and / or Fas binding molecules are added which bind the Fas to T cells of the transplant and / or TRAIL receptor binding molecules are added, bind the TRAIL receptors to T cells of the graft, or
- T cells are switched off and / or they are driven into programmed cell death (apoptosis) and / or they differentiate into regulatory T cells if the T cells simultaneously present an antigen with their T cell receptor detect.
- Molecules that bind Fas and / or TRAIL receptors to T cells in the transplant can cause T cells to enter programmed cell death (apoptosis)
- the binding molecules are crosslinked, which e.g. by other binding molecules, e.g. Antibodies can happen, which in turn bind the binding molecules against CD83, CD80, CD86, CD40, CTLA4, Fas, TRAIL receptors. Networking promotes the desired effect.
- the cells according to the invention can also be represented in whole or in part by immature dendritic cells (DC; e.g. those derived in vitro). Due to the lack of costimulation in immature DCs, T cells (as in A.) are removed
- the cell according to the invention can also have at least one gene for a
- T cells (as in A.) can be forced to programmed cell death (apoptosis).
- the cell according to the invention can also contain at least one gene for a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor.
- TRAIL tumor necrosis factor-related apoptosis-inducing ligand
- TRAIL receptor binding molecules on the plasma membrane of dendritic cells can force T cells (as in A.) to programmed cell death (apoptosis).
- the cell according to the invention can also be added by adding aspirin, la, 25 dihydroxyvitamin D3, la, 25 (OH) 2-16-ene-23-yne-26,27-hexafluoro-19-nor-vitamin D3 (D3 analog), vitamin D3, glucocorticoids are treated (Adorini et al 2001; Griffin et al 2001; Griffin et al 2000; Ralphstein et al 2001; Penna & Adorini 2000; Penna & Adorini 2001) (WO 01/24818).
- dendritic cells remain in a state which limits the immunostimulatory properties of the dendritic cells.
- the reduced costimulation switches off T cells (as in A.) and / or drives them to programmed cell death (apoptosis) and / or differentiates them into regulatory T cells.
- the cell according to the invention can also be transfected with at least one gene for a CTLA4 binding molecule.
- CTLA4 binding molecules By expressing CTLA4 binding molecules on the plasma membrane of dendritic cells, T cells can be switched off and / or driven into programmed cell death (apoptosis) and / or differentiated into regulatory T cells. G.
- the cell according to the invention can also be transfected with at least one gene for a CD83 binding molecule and / or for B7 (CD80 / CD86) binding molecules and / or for a CD40 binding molecule.
- a CD83 binding molecule and / or for B7 (CD80 / CD86) binding molecules and / or for a CD40 binding molecule By expressing CD83 binding molecules and / or B7 (CD80 / CD86) binding molecules and / or CD40 binding molecules in the endoplasmic reticulum and / or Golgi and / or extracellularly and / or on the plasma membrane of dendritic cells, T cells can be switched off and on / or driven into programmed cell death (apoptosis) and / or differentiated into regulatory T cells.
- the cell according to the invention can also be transfected with at least one gene for IL-10.
- Expression of IL-10 from dendritic cells prevents the dendritic cells from activating T cells (Corinti et al 2001), so that T cells can be switched off and / or driven into programmed cell death (apoptosis) and / or be differentiated into regulatory T cells.
- the cell according to the invention can be induced by incubation with the interferons (IFNa or IFN ⁇ or IFNß) to synthesize tumor necrosis factor-related apoptosis inducing ligand (TRAIL).
- IFNa or IFN ⁇ or IFNß interferons
- TRAIL- on the plasma membrane of dendritic cells can force T cells (as in A.) to programmed cell death (apoptosis) (Liu et al 2001; Fanger et al 1999).
- One of the procedures (A.-I.) and / or any sequence of these procedures (A.-I.) is used to treat the cell according to the invention in vitro with allogeneic stem cells (eg including lymphocytes) or with allogeneic T cells or incubate with allogeneic lymphocytes from a foreign stem cell transplant donor (e.g. bone marrow).
- allogeneic stem cells eg including lymphocytes
- allogeneic T cells e.g. allogeneic T cells
- allogeneic lymphocytes e.g. bone marrow
- the cells mentioned which come from the recipient of the transplant and in cancer patients, esp especially those with leukaemias that can contain cancer cells can be treated in a preferred embodiment of the method according to the invention before incubation with the transplant in such a way that these cells will not proliferate. This is preferably achieved by irradiating these cells.
- the cell according to the invention can also be transfected with at least one gene for IL-10.
- Expression of IL-10 from dendritic cells prevents the dendritic cells from activating T cells (Corinti et al 2001), so that T cells can be switched off and / or driven into programmed cell death (apoptosis) and / or to be differentiated into regulatory T cells.
- the cell according to the invention can be induced by incubation with the interferons (IFNa or IFN ⁇ or IFNß) to synthesize tumor necrosis factor-related apoptosis inducing ligand (TRAIL).
- IFNa or IFN ⁇ or IFNß interferons
- TRAIL tumor necrosis factor-related apoptosis inducing ligand
- Expression of TRAIL- on the plasma membrane of dendritic cells can force T cells (as in A.) to programmed cell death (apoptosis) (Liu et al 2001; Fanger et al 1999).
- One of the procedures (A.-I.) and / or any sequence of these procedures (A.-I.) is used to treat the cell according to the invention in vitro with allogeneic stem cells (eg including lymphocytes) or with allogeneic T cells or incubate with allogeneic lymphocytes from a foreign stem cell transplant donor (e.g. bone marrow).
- allogeneic stem cells eg including lymphocytes
- allogeneic T cells e.g. allogeneic T cells
- allogeneic lymphocytes e.g. bone marrow
- the cells mentioned which originate from the recipient of the transplant and can contain cancer cells in cancer patients, in particular those with leukemia, can be found in ei ner preferred embodiment of the method according to the invention are treated before incubation with the graft so that proliferation of these cells will not occur. This is preferably achieved by irradiating these cells.
- the non-alloreactive, but allologic T-cells positively selected by one of these procedures and / or any sequence of these procedures are presented to the patient together with the allologic stem cells (e.g. bone marrow)
- graft-versus-leukemia effect (GvL) is obtained, but none, or a significantly reduced graft-versus-host disease (GvHD).
- the CD83 binding molecules can preferably be antibodies, monoclonal antibodies, F (ab) 2 , single chain antibodies (scFv), and / or Fab fragments.
- the proteins which have affine structures for B7 receptors can preferably be CTLA4, CTLA4 derivatives (eg CTLA4Ig), CD28, antibodies, F (ab) 2 , scFv and / or Fab fragments.
- the proteins which have structures affinity to CD40 receptors can preferably be CD40L, CD40L derivatives, antibodies, F (ab) 2 , scFv and / or Fab fragments.
- the proteins which have affine structures for CTLA4 (CD152) receptors can preferably be antibodies, F (ab) 2 , scFv and / or Fab fragments.
- the proteins which have affine structures for Fas ligands can preferably be FasL, FasL derivatives, antibodies, F (ab) 2 , scFv and / or Fab fragments.
- the proteins which have affine structures for TRAIL receptors can preferably be TRAIL, TRAIL derivatives, antibodies, F (ab) 2 , scFv and / or Fab fragments.
- the method according to the invention can be based on genetic engineering interventions on the patient's own cells (pre-cells: stem cells, monocytes, DCs, CD34 + stem cells, CD34 + progenitor stem cells and / or B cells).
- the interventions take place by means of suitable probes and bring about the reduction of CD83 molecules and possibly B7 molecules and / or CD40 molecules by hindering or preventing the formation of the molecule on the surface of the antigen-presenting cells and / or CTLA4 binding Molecules, preferably antibodies, and / or the production of Fas binding molecules, preferably FasL and / or the production of TRAIL receptor binding molecules, preferably TRAIL and / or the production of IL-10.
- Transfection of the pre-cells causes expression of Fas binding molecules and / or TRAIL receptor binding molecules and / or IL-10 and / or B7 binding molecules and / or CTLA4 binding molecules and / or CD83 binding molecules and / or CD40 binding molecules.
- the nucleic acids can be DNA, RNA, oligonucleotides, polynucleotides, ribozymes or peptide nucleic acids (PNA).
- the DNA contains regulatory elements such as enhancers, promoters, polyA-coding 3'-ends for the transcription of the DNA into RNA.
- the RNA in turn should contain regulatory elements for translating the RNA into protein.
- the nucleic acids are provided with a signal sequence which effects the transport of the expression products to the plasma membrane.
- nucleic acids encode a signal sequence which causes the expression products to remain in the respective cell compartments.
- the cells mentioned can be transfected ex vivo by treatment with viruses, viral vectors, bacterial vectors, plasmids which are suitable by viral gene transfer, electroporation techniques, iontophoresis, ballistic methods and / or other techniques for introducing molecules into eukaryotic cells.
- Said cell can be treated with viruses, viral vectors, bacterial vectors, plasmids by viral gene transfer, electroporation techniques, iontophoresis, ballistic methods and / or other techniques for introducing molecules into a cell with increased production of Fas binding molecule and / or TRAIL receptor binding molecule and / or CD83 binding molecules, CD40 binding molecules, B7 (CD80 / CD86) binding molecules, CTLA4 binding molecule, IL-10 are transfected, whereby T cells which have allologic antigens, for example on MHC -Molecules are presented to the antigen- bind presenting cell, be switched off.
- viruses viral vectors, bacterial vectors, plasmids by viral gene transfer, electroporation techniques, iontophoresis, ballistic methods and / or other techniques for introducing molecules into a cell with increased production of Fas binding molecule and / or TRAIL receptor binding molecule and / or CD83 binding molecules, CD40 binding molecules, B7 (CD80
- Molecules such as antibodies, proteins, peptides, peptidomimetics, CTLA4, CTLA4 derivatives such as CTLA4Ig, CD28, CD40L and / or constituents and / or combinations of these molecules, which bind, for example, B7-1, B7-2, CD83, CD40, can be used as binding molecules , serve. These molecules hinder stimulation and / or co-stimulation of T cells which take place in the presence of an alloantigen presentation and are brought into contact with the cell according to the invention.
- the molecules can be generated by vehicles such as liposomes, hydrogels,
- Nucleic acids can be transferred in particular by viruses, viral vectors, bacterial vectors, plasmids, which are transferred into the monoantigenic antigen-presenting cell and / or the antigen-presenting cell by electroporation techniques, iontophoresis, ballistic methods and / or other techniques for introducing molecules.
- the APC or pre-cell which consists of the group consisting of stem cells, monocytes, DCs, CD34 + stem cells, CD34 + progenitor stem cells and / or B-
- a medicament containing at least one cell according to the invention is also claimed according to the invention.
- the medicament according to the invention is preferably formulated as an infusion solution for intravenous or intraperitoneal application. The formulation is chosen so that when the drug is administered there is no significant impairment of the effectiveness of the antigen-presenting cell according to the invention.
- physiological saline is preferred as the infusion solution.
- other solutions with a pH of 5.5 to 8.5 are also suitable.
- Serum for example human serum, autologous serum or serum of other species, solutions with plasma substitutes, such as polyvinylpyrrolidone, are also suitable.
- plasma substitutes such as polyvinylpyrrolidone
- 0.5 ml to 500 ml should be applied.
- the antigen-presenting cell according to the invention can be used in particular for the production of a medicament for the treatment of immune reactions against allologic tissue features or for the prevention of GvHD.
- the immune reactions to be treated are connected with allologic tissue characteristics, their gene sequences and / or partial sequences ⁇ , in particular major histocompatibility complexes, MHC I, MHC II, rhesus factor, minor histocompatibility antigens (minor histocompatibility antigens)
- a use is claimed according to the invention in which the binding molecules are crosslinked in a preferred embodiment, which is achieved by other binding molecules, e.g. Antibodies, which in turn bind the molecules against CD83, CD80,
- Bind CD86, CD40, CTLA4, Fas, TRAIL receptors Such cross-linking enhances the effect of these binding molecules.
- the ex vivo selected cells are infused into the patient and the patient is then subjected to an in vivo treatment with IL-2.
- the cells selected ex vivo can also be incubated ex vivo with IL-2 or other stimulants such as phytohemaglutinin (PHA) and then infused into the patient. It has been shown that the GvL effect can be enhanced in this way.
- PHA phytohemaglutinin
- helper CD4 + T cells and cytotoxic CD8 + T cells C3H mouse
- target cells such as A20 cells (lymphoma cells from Balb / c) and Balb / c-DC after they were incubated with differently treated DC.
- the CD8 + T cells are referred to as effector cells.
- A20 cells and Balb / c-DC are the target cells.
- the cytotoxicity assay consists of two incubations. The first is used to incubate allologic T cells (C3H) with "autologous" DC (Balb / c). In the second incubation (the actual cytotoxicity assay), the T cells are removed from the first incubation and incubated with target cells for 4 h.
- the target cells are lysed by allologic, cytotoxic CD8 + T cells, to an extent that depends on how many allologic T cells react against the foreign target cells.
- Mature and immature DC were used as DC. These should act differently on the T cells. Mature DC stimulate T cells, while immature DC turn off T cells. Mature DCs blocked in Kostimulus B7 turn off T cells. The experimental approach is shown in Fig. 1 and Fig. 2. Execution:
- Immature DC (imDC from immature DC) were obtained from bone marrow from Balb / c-
- the spleens were prepared from two C3H mice and the T cells isolated using MACS.
- the isolated T cells were sown with a cell density of 5xl0 5 / 500 ⁇ l complete medium in a well of a 24-well plate and thus above sea level. incubated at 37 ° C in the incubator.
- the complete medium had the following composition:
- the complete medium was set up as follows:
- 100 ml of 10 x RPMI were diluted with 870 ml of water.
- 30 ml of NaHCO 3 , 20 ml of L-glutamine and 10 ml of sodium pyruvate were pipetted.
- the finished medium was mixed by swirling and could then be portioned. Then the appropriate amount of fetal calf serum and 1 ml of 50 mM mercaptoethanol are added.
- the DCs were prepared the day before C3H T cells with a cell density of lxl0 4/500 .mu.l of complete medium (per well of a 24-well plate) was added.
- the DC were incubated with T cells in a ratio of 1:50 (in cell numbers 1x10 4 : 5x10 5 per well of a 24-well plate) for 6 days (FIG. 4).
- the cells After the first incubation, the cells (all cells -> also the Balb / c-DC) were removed from the well and incubated for 4 hours with the target cells A20 cells or Balb / c-DC (Fig. 4). 5xl0 3 target cells and lxlO 5 effector cells were used for each approach. The total volume was 200 ⁇ l complete medium.
- A20 cells were from a continuous cell culture. They are a Balb / c B cell lymphoma line. BALB / c DC
- Balb / c-DC were differentiated from bone marrow cells and used as target cells in the immature stage on day 7.
- TruCount beads Becton
- the batches were stained with propidium iodide (PI) shortly before the measurement.
- PI propidium iodide
- the cells that were CFSE / PI double positive were considered for the evaluation.
- the target cells that died without the influence of T cells were determined as a control.
- the effectiveness of the B7 blockade was determined using anti-CD86 (B7-2, aCD86) monoclonal antibodies. If the CD86 signal becomes smaller in the FACS, there are fewer unblocked B7-2 molecules on the cell surface of the DC. Fig. 5 shows that the TNF ⁇ treated and therefore mature DC have a higher CD86 expression than the immature DC. CD86 could be blocked in mature and immature DC. Irradiation had no significant effect on CD86 expression.
- Fig. 6 shows the percentage of the lysed target cells as a function of the irradiated / unirradiated or blocked / unblocked DC (during the first incubation), which were incubated with the effector cells.
- immature DC blocked and unblocked
- DC blocked mature DC
- Unmodified DC on the other hand, have promoted the activation of alloantigen-specific T cells.
- TRAIL tumor necrosis factor-related apoptosis-inducing ligand
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002321240A AU2002321240A1 (en) | 2001-07-21 | 2002-07-19 | Ex-vivo selection of t-cells with reduced alloreactivity and use thereof in bone marrow transplantations |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10135615.3 | 2001-07-21 | ||
DE10135615A DE10135615A1 (de) | 2001-07-21 | 2001-07-21 | Ex vivo Selektion von T-Zellen |
EP01121806.2 | 2001-09-11 | ||
EP01121806A EP1291414A1 (fr) | 2001-09-11 | 2001-09-11 | Sélection ex vivo de celulles T présentant une alloréacitvité diminuée (effet greffon-versus-hôte dimimué et effet greffon-versus-leucémie augmenté) et utilisation de ces cellues dans des greffes de moelle osseuse |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003012080A2 true WO2003012080A2 (fr) | 2003-02-13 |
WO2003012080A3 WO2003012080A3 (fr) | 2003-08-28 |
Family
ID=26009749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008052 WO2003012080A2 (fr) | 2001-07-21 | 2002-07-19 | Selection ex vivo de lymphocytes t |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002321240A1 (fr) |
WO (1) | WO2003012080A2 (fr) |
-
2002
- 2002-07-19 AU AU2002321240A patent/AU2002321240A1/en not_active Abandoned
- 2002-07-19 WO PCT/EP2002/008052 patent/WO2003012080A2/fr not_active Application Discontinuation
Non-Patent Citations (7)
Title |
---|
APPELBAUM FREDERICK R: "Haematopoietic cell transplantation as immunotheraphy." NATURE (LONDON), Bd. 411, Nr. 6835, 2001, Seiten 385-389, XP002187722 ISSN: 0028-0836 * |
APPLEMAN LEONARD J ET AL: "Helper T cell anergy: From biochemistry to cancer pathophysiology and therapeutics." JOURNAL OF MOLECULAR MEDICINE (BERLIN), Bd. 78, Nr. 12, 2001, Seiten 673-683, XP002187721 ISSN: 0946-2716 * |
BLAZAR BRUCE R ET AL: "CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses." JOURNAL OF CLINICAL INVESTIGATION, Bd. 102, Nr. 3, 1. August 1998 (1998-08-01), Seiten 473-482, XP002187718 ISSN: 0021-9738 * |
CHAMPLIN RICHARD ET AL: "Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy." BRITISH JOURNAL OF HAEMATOLOGY, Bd. 111, Nr. 1, Oktober 2000 (2000-10), Seiten 18-29, XP002187720 ISSN: 0007-1048 * |
GUINAN EVA C ET AL: "Transplantation of anergic histoincompatible bone marrow allografts." NEW ENGLAND JOURNAL OF MEDICINE, Bd. 340, Nr. 22, 9. Juni 1999 (1999-06-09), Seiten 1704-1714, XP002187717 ISSN: 0028-4793 * |
LU L ET AL: "ADENOVIRAL DELIVERY OF CTLA4LG INTO MYELOID DENDRITIC CELLS PROMOTES THEIR IN VITRO TOLEROGENICITY AND SURVIVAL IN ALLOGENEIC RECIPIENTS" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, Bd. 6, Nr. 4, 1999, Seiten 554-563, XP000946114 ISSN: 0969-7128 * |
ZELLER ET AL: "Induction of CD4+ T Cell Alloanitgen-Specific Hyporesponsiveness by Il-10 and TGF-beta" THE JOURNAL OF IMMUNOLOGY, Bd. 163, 1999, Seiten 3684-3691, XP002187719 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002321240A1 (en) | 2003-02-17 |
WO2003012080A3 (fr) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102017127984B4 (de) | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen | |
DE19833476B4 (de) | Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie | |
DE69834257T2 (de) | Natürliche killerzelllinien und verfahren zu ihrer verwendung | |
Benvenuto et al. | Human mesenchymal stem cells promote survival of T cells in a quiescent state | |
DE69328481T2 (de) | In vitro bildung von dentritischen zellen | |
DE60038503T2 (de) | AKTIVIERUNG DES IMMUNSYSTEMS DURCH EINEN ANTIGEN UND EINEN NF-kappaB AUSLÖSER | |
US12060577B2 (en) | Compositions for expanding natural killer cells | |
DE69910362T2 (de) | Anwendung der mesenchymalen stammzellen als immunsuppressiva | |
DE69729455T2 (de) | Methode und zusammensetzungen zum erlangen reifer dendritischer zellen | |
DE69231250T2 (de) | Kombinierte zelluläre und immunsuppressive therapien | |
Achita et al. | Infusion of ex-vivo expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease | |
DE69734989T2 (de) | Antigenpräsentierende zellen, ein verfahren zur deren herstellung und deren verwendung als zelluläre impfstoffen | |
DE69634982T2 (de) | Verfahren zur steigerung von hematopoietischen zellen | |
WO2008151846A2 (fr) | Immunomodulation des lymphocytes t par des préparations de cellules du placenta | |
Chute et al. | Ex vivo culture rescues hematopoietic stem cells with long-term repopulating capacity following harvest from lethally irradiated mice | |
WO2004072264A2 (fr) | Determination de la destinee par hes1 dans des cellules souches et progenitrices hematopoietiques et utilisation | |
EP0693120B1 (fr) | Lymphocites t tumoricides | |
Olsson et al. | Production, characteristics and mode of action of hemopoietic growth inhibitors in myeloid leukemias | |
DE10139428A1 (de) | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika | |
EP2633034B1 (fr) | CELLULES DENDRITIQUES À VOIE DE SIGNALISATION NFkB MANIPULÉE | |
EP3967753A2 (fr) | Procédé de culture de cellules immunitaires allogéniques, culture de cellules immunitaires ainsi obtenues, et agent thérapeutique de cellules immunitaires les comprenant | |
KR101432881B1 (ko) | 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물 | |
EP1291414A1 (fr) | Sélection ex vivo de celulles T présentant une alloréacitvité diminuée (effet greffon-versus-hôte dimimué et effet greffon-versus-leucémie augmenté) et utilisation de ces cellues dans des greffes de moelle osseuse | |
DE60016567T2 (de) | Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode | |
DE10135615A1 (de) | Ex vivo Selektion von T-Zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |